Opaganib in Coronavirus Disease 2019 Pneumonia: Results of a Randomized, Placebo-Controlled Phase 2a Trial

BACKGROUND: Opaganib, an oral sphingosine kinase-2 inhibitor with antiviral and anti-inflammatory properties, was shown to inhibit severe acute respiratory syndrome coronavirus 2 replication in vitro. We thus considered that opaganib could be beneficial for moderate to severe coronavirus disease 201...

Descripción completa

Detalles Bibliográficos
Autores principales: Winthrop, Kevin L, Skolnick, Alan W, Rafiq, Adnan M, Beegle, Scott H, Suszanski, Julian, Koehne, Guenther, Barnett-Griness, Ofra, Bibliowicz, Aida, Fathi, Reza, Anderson, Patricia, Raday, Gilead, Eagle, Gina, Ben-Yair, Vered Katz, Minkowitz, Harold S, Levitt, Mark L, Gordon, Michael S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9129144/
https://www.ncbi.nlm.nih.gov/pubmed/35832268
http://dx.doi.org/10.1093/ofid/ofac232

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9129144/
https://www.ncbi.nlm.nih.gov/pubmed/35832268
http://dx.doi.org/10.1093/ofid/ofac232

Ejemplares similares